Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer

Natasha Halasa, Janet A. Englund, Sharon Nachman, Geoffrey A. Weinberg, Victor C. Huber, Kim Allison, Filip Dubovsky, Tingting Yi, Jonathan Mccullers, Patricia M. Flynn

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: The safety of intranasal live-attenuated influenza vaccine (LAIV) in immunocompromised children with cancer is unknown. The objective of this study was to describe the safety and immunogenicity of LAIV in mild to moderately immunocompromised children with cancer. Methods: We conducted a multicenter, randomized, double-blind study of LAIV versus placebo in children aged 5-17 years with cancer. LAIV (frozen formulation) or allantoic fluid/buffer was administered intranasally. Reactogenicity, adverse events, blood for immune assays, and nasal swabs for viral shedding were obtained during 5 visits over the first 42 days postvaccination; information concerning serious adverse events (SAEs) was collected for 180 days. Results: 20 subjects were enrolled (LAIV, n= 10; placebo, n= 10) with a mean age of 12.2 years. Ten subjects had hematologic malignancy (LAIV, n= 4; placebo, n= 6); 10 subjects had solid tumors (LAIV, n= 6; placebo, n= 4). One subject was excluded from immunogenicity analysis for not receiving a full dose of LAIV. LAIV resulted in an increased incidence of runny nose/nasal congestion occurring in all LAIV recipients; no related SAEs were observed. Four of 10 LAIV recipients shed vaccine virus, with none exceeding 7-10 days duration. LAIV demonstrated modest immunogenicity by hemagglutination inhibition (≥4 fold rise for any strain, 33%) and microneutralization assays (≥4 fold rise for any strain, 44%). Conclusion: In this small pilot study conducted in mild to moderately immunocompromised children with cancer, runny nose/nasal congestion was increased in LAIV recipients, no related SAEs occurred, and prolonged viral shedding was not detected. Moderate immunogenicity was demonstrated in this small group of individuals. (ClinTrials.gov: NCT00112112).

Original languageEnglish (US)
Pages (from-to)4110-4115
Number of pages6
JournalVaccine
Volume29
Issue number24
DOIs
StatePublished - May 31 2011
Externally publishedYes

Fingerprint

Attenuated Vaccines
Influenza Vaccines
influenza
vaccines
Safety
neoplasms
Neoplasms
Nose
placebos
Placebos
immune response
Virus Shedding
viral shedding
Nose Neoplasms
allantoic fluid
Hemagglutination
Hematologic Neoplasms
assays
Double-Blind Method
hemagglutination

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Halasa, N., Englund, J. A., Nachman, S., Weinberg, G. A., Huber, V. C., Allison, K., ... Flynn, P. M. (2011). Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer. Vaccine, 29(24), 4110-4115. https://doi.org/10.1016/j.vaccine.2011.03.097

Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer. / Halasa, Natasha; Englund, Janet A.; Nachman, Sharon; Weinberg, Geoffrey A.; Huber, Victor C.; Allison, Kim; Dubovsky, Filip; Yi, Tingting; Mccullers, Jonathan; Flynn, Patricia M.

In: Vaccine, Vol. 29, No. 24, 31.05.2011, p. 4110-4115.

Research output: Contribution to journalArticle

Halasa, N, Englund, JA, Nachman, S, Weinberg, GA, Huber, VC, Allison, K, Dubovsky, F, Yi, T, Mccullers, J & Flynn, PM 2011, 'Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer', Vaccine, vol. 29, no. 24, pp. 4110-4115. https://doi.org/10.1016/j.vaccine.2011.03.097
Halasa N, Englund JA, Nachman S, Weinberg GA, Huber VC, Allison K et al. Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer. Vaccine. 2011 May 31;29(24):4110-4115. https://doi.org/10.1016/j.vaccine.2011.03.097
Halasa, Natasha ; Englund, Janet A. ; Nachman, Sharon ; Weinberg, Geoffrey A. ; Huber, Victor C. ; Allison, Kim ; Dubovsky, Filip ; Yi, Tingting ; Mccullers, Jonathan ; Flynn, Patricia M. / Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer. In: Vaccine. 2011 ; Vol. 29, No. 24. pp. 4110-4115.
@article{381186045d404dd9926a7e8ab87a5e9c,
title = "Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer",
abstract = "Background: The safety of intranasal live-attenuated influenza vaccine (LAIV) in immunocompromised children with cancer is unknown. The objective of this study was to describe the safety and immunogenicity of LAIV in mild to moderately immunocompromised children with cancer. Methods: We conducted a multicenter, randomized, double-blind study of LAIV versus placebo in children aged 5-17 years with cancer. LAIV (frozen formulation) or allantoic fluid/buffer was administered intranasally. Reactogenicity, adverse events, blood for immune assays, and nasal swabs for viral shedding were obtained during 5 visits over the first 42 days postvaccination; information concerning serious adverse events (SAEs) was collected for 180 days. Results: 20 subjects were enrolled (LAIV, n= 10; placebo, n= 10) with a mean age of 12.2 years. Ten subjects had hematologic malignancy (LAIV, n= 4; placebo, n= 6); 10 subjects had solid tumors (LAIV, n= 6; placebo, n= 4). One subject was excluded from immunogenicity analysis for not receiving a full dose of LAIV. LAIV resulted in an increased incidence of runny nose/nasal congestion occurring in all LAIV recipients; no related SAEs were observed. Four of 10 LAIV recipients shed vaccine virus, with none exceeding 7-10 days duration. LAIV demonstrated modest immunogenicity by hemagglutination inhibition (≥4 fold rise for any strain, 33{\%}) and microneutralization assays (≥4 fold rise for any strain, 44{\%}). Conclusion: In this small pilot study conducted in mild to moderately immunocompromised children with cancer, runny nose/nasal congestion was increased in LAIV recipients, no related SAEs occurred, and prolonged viral shedding was not detected. Moderate immunogenicity was demonstrated in this small group of individuals. (ClinTrials.gov: NCT00112112).",
author = "Natasha Halasa and Englund, {Janet A.} and Sharon Nachman and Weinberg, {Geoffrey A.} and Huber, {Victor C.} and Kim Allison and Filip Dubovsky and Tingting Yi and Jonathan Mccullers and Flynn, {Patricia M.}",
year = "2011",
month = "5",
day = "31",
doi = "10.1016/j.vaccine.2011.03.097",
language = "English (US)",
volume = "29",
pages = "4110--4115",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "24",

}

TY - JOUR

T1 - Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer

AU - Halasa, Natasha

AU - Englund, Janet A.

AU - Nachman, Sharon

AU - Weinberg, Geoffrey A.

AU - Huber, Victor C.

AU - Allison, Kim

AU - Dubovsky, Filip

AU - Yi, Tingting

AU - Mccullers, Jonathan

AU - Flynn, Patricia M.

PY - 2011/5/31

Y1 - 2011/5/31

N2 - Background: The safety of intranasal live-attenuated influenza vaccine (LAIV) in immunocompromised children with cancer is unknown. The objective of this study was to describe the safety and immunogenicity of LAIV in mild to moderately immunocompromised children with cancer. Methods: We conducted a multicenter, randomized, double-blind study of LAIV versus placebo in children aged 5-17 years with cancer. LAIV (frozen formulation) or allantoic fluid/buffer was administered intranasally. Reactogenicity, adverse events, blood for immune assays, and nasal swabs for viral shedding were obtained during 5 visits over the first 42 days postvaccination; information concerning serious adverse events (SAEs) was collected for 180 days. Results: 20 subjects were enrolled (LAIV, n= 10; placebo, n= 10) with a mean age of 12.2 years. Ten subjects had hematologic malignancy (LAIV, n= 4; placebo, n= 6); 10 subjects had solid tumors (LAIV, n= 6; placebo, n= 4). One subject was excluded from immunogenicity analysis for not receiving a full dose of LAIV. LAIV resulted in an increased incidence of runny nose/nasal congestion occurring in all LAIV recipients; no related SAEs were observed. Four of 10 LAIV recipients shed vaccine virus, with none exceeding 7-10 days duration. LAIV demonstrated modest immunogenicity by hemagglutination inhibition (≥4 fold rise for any strain, 33%) and microneutralization assays (≥4 fold rise for any strain, 44%). Conclusion: In this small pilot study conducted in mild to moderately immunocompromised children with cancer, runny nose/nasal congestion was increased in LAIV recipients, no related SAEs occurred, and prolonged viral shedding was not detected. Moderate immunogenicity was demonstrated in this small group of individuals. (ClinTrials.gov: NCT00112112).

AB - Background: The safety of intranasal live-attenuated influenza vaccine (LAIV) in immunocompromised children with cancer is unknown. The objective of this study was to describe the safety and immunogenicity of LAIV in mild to moderately immunocompromised children with cancer. Methods: We conducted a multicenter, randomized, double-blind study of LAIV versus placebo in children aged 5-17 years with cancer. LAIV (frozen formulation) or allantoic fluid/buffer was administered intranasally. Reactogenicity, adverse events, blood for immune assays, and nasal swabs for viral shedding were obtained during 5 visits over the first 42 days postvaccination; information concerning serious adverse events (SAEs) was collected for 180 days. Results: 20 subjects were enrolled (LAIV, n= 10; placebo, n= 10) with a mean age of 12.2 years. Ten subjects had hematologic malignancy (LAIV, n= 4; placebo, n= 6); 10 subjects had solid tumors (LAIV, n= 6; placebo, n= 4). One subject was excluded from immunogenicity analysis for not receiving a full dose of LAIV. LAIV resulted in an increased incidence of runny nose/nasal congestion occurring in all LAIV recipients; no related SAEs were observed. Four of 10 LAIV recipients shed vaccine virus, with none exceeding 7-10 days duration. LAIV demonstrated modest immunogenicity by hemagglutination inhibition (≥4 fold rise for any strain, 33%) and microneutralization assays (≥4 fold rise for any strain, 44%). Conclusion: In this small pilot study conducted in mild to moderately immunocompromised children with cancer, runny nose/nasal congestion was increased in LAIV recipients, no related SAEs occurred, and prolonged viral shedding was not detected. Moderate immunogenicity was demonstrated in this small group of individuals. (ClinTrials.gov: NCT00112112).

UR - http://www.scopus.com/inward/record.url?scp=79956104763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956104763&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.03.097

DO - 10.1016/j.vaccine.2011.03.097

M3 - Article

VL - 29

SP - 4110

EP - 4115

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 24

ER -